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Abstract
Pain is the hallmark of acute pancreatitis
and it is localized in the epigastrium in more
than 60% of patients having mild or severe dis-
ease. Acute pancreatitis may mimic other dis-
eases such as acute coronary syndrome. In
addition, the acute illness of the pancreas is
associated with a number of metabolic abnor-
malities, such as hypocalcemia and hypophos-
phatemia, which may cause hemodynamic
changes and variations in the concentration of
ionized calcium. In turn, these have been
directly correlated to changes in myocardial
contractility. The aim of this paper is to review
the current literature on the involvement of
heart during the course of acute pancreatitis
and also to evaluate experimental and clinical
data on this topic.
Introduction
Pain is the hallmark of acute pancreatitis and
it is localized in the epigastrium in more than
60% of patients having mild or severe disease.1
Sometimes acute pancreatitis may mimic other
diseases and, in particular, acute coronary syn-
drome.2 In addition, the acute illness of the pan-
creas is associated with a number of metabolic
abnormalities, such as hypocalcemia and
hypophosphatemia which may cause hemody-
namic changes and variations in the concentra-
tion of ionized calcium have been directly corre-
lated to changes in myocardial contractility.3 Our
aim is to review the current literature on the
involvement of heart during the course of acute
pancreatitis and to evaluate experimental and
clinical data on this topic.
Pathogenesis of acute pancre-atitis
The main etiology of acute pancreatitis, at
least in Western countries remains that of bil-
iary origin. In fact, biliary forms represented
the most frequent etiological category (69.3%),
while alcoholic forms occurred in only 6.6%; all
together the remaining etiologies (post-
surgery, post-endoscopic cholangiopancreatog-
raphy, traumatic, hyperlipemic, drug-induced
and pancreas divisum) accounted for 7.1% of
cases and 17.1% remained without a definite
etiological factor.4 The current theory of acute
biliary pancreatitis is the common bile duct
obstruction, which increases pancreatic duct
pressure that led to trypsin activation and pan-
creatic auto-digestion.5 Although pancreatic
duct obstruction may play an important role in
the pathogenesis of gallstone pancreatitis, it is
not sufficient to cause the morphological
changes of acute pancreatitis,6 indicating that
other events must occur if the changes
induced by pancreatic duct obstruction lead to
acute pancreatitis. ossible that pancreatic aci-
nar hyperstimulation, in the presence of duct
obstruction, triggers and exacerbates acute
pancreatitis.7 Probably a common pathogenic
pathway that triggers various forms of acute
pancreatitis may involve exocrine increased
pancreatic hyperstimulation, pancreatic duct
pressure, active trypsin reflux, and unregulat-
ed activation of trypsin within pancreatic aci-
nar cells. When intracellular protective mecha-
nisms aimed to prevent trypsinogen activation
or reduce trypsin activity are overwhelmed,
acute pancreatitis occurs.
Pathophysiology of acute pancreatitis
From experimental studies it has been postu-
lated that acute pancreatitis evolves in 3 phas-
es:7 in the first phase, there are intrapancreatic
trypsinogen activation and acinar cell injury as
a result of release of trypsin; subsequently,
there is an intrapancreatic inflammatory reac-
tion that leads to the third phase characterized
by development of system inflammatory
response syndrome and multiple organ system
dysfunction.8 Proteolytic enzymes such as
trypsin, lipase and phospholipase A, kinins such
as bradykinin, cytokines, and other active pep-
tides such as trypsinogen activation peptide and
carboxypeptidase activation peptide are liberat-
ed from the inflamed pancreas and they trans-
form a single-organ disease into a multisystem
disease.8 As shown in Figure 1 the pathogenesis
and evolution of acute pancreatitis correlate
with the clinical phases of the disease.8
The experimental evidence
In experimental animals, myocardium pro-
duces cytokines locally under stress events and
IL-6 production is an early event. In addition
other cytokines are also produced by the heart
and could be correlated with the echocardio-
graphic left ventricular change; for example
the production of TNF-alpha occurs in the
same period of histological findings as acute
myocardial damage, whereas TGF-beta is
released in the subsequent period.9 In addi-
tion, there is experimental evidence in support
of the existence of an intrinsic renin-
angiotensin system in the pancreas. The pan-
creatic renin-angiotensin system is activated
in experimental acute pancreatitis and may
cause cardiac and alterations10 in humans as
well.11
The clinical evidence
Drummond first reported electrocardio-
graphic changes in patients with abdominal
pain.12 The causes of these alterations were
hypothesized due to sympathetic adrenergic
activation from a parasympathetic reflex,
reduction of intra-cellular potassium, activa-
tion of enzymatic systems, reabsorption of
toxic substances.13 Clinical studies have
identified electrocardiographic changes and
pericardium alterations due to hemodynamic
status.14,15 Experimental studies have also
reported that in acute pancreatitis there are
myocardial ultrastructural disturbances,
including interstitial edema and cardiomy-
ocyte hypoxia,16 myofiber overcontractility,
intercellular edema between the cardiomy-
ocytes, and cardiomyocyte hypertrophy with
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collagenization of myocardial stroma.17 The
electrocardiographic alterations in acute
pancreatitis are various, say tachyarrhythmia
or bradyarrhythmias, atrial flutter and atrial
fibrillation, supraventricular premature con-
tractions, short PR interval, QRS prolonga-
tion, various bundle-branch blocks (such as
left and right bundle-branch block, and left
anterior hemiblock), non-specific changes in
depolarization, decreased T-wave voltage, T-
wave changes, and ST-segment abnormali-
ties. These alterations are often seen in
approximately 50% of patients.18,19 Evaluation
of left ventricular function in the early phas-
es of acute pancreatitis has also been inves-
tigated, showing an impairment of contractil-
ity in a significant portion of patients with
acute pancreatitis.20 Echocardiographic
assessment based on clinical parameters of
severity may help to select those patients
who merit highly intensive treatment.20
The laboratory evidence
Easy and largely available serum markers
are required to rapidly identify those patients
having a cardiac involvement during the
course of acute pancreatitis.21 In a recent
study, we evaluated the presence of elevated
levels of high-sensitivity cardiac Troponin
(hs-TnT) in patients with acute pancreati-
tis,22 and we found that more than 35% of
them had high serum levels of this cardiac
marker. The time course of serum troponin T
in the early phases of acute pancreatitis is
reported in Figure 2.22 However, the absence
of any clinical and electrocardiographic fea-
tures of acute coronary syndrome in our
patients suggests that abnormally high
results should be interpreted as of non-
ischemic origin.23,24 In conclusion, we believe
that troponin I should be used in assessing
cardiac damage in acute pancreatitis
patients, but additional studies exploring this
possibility are needed.
The future way
Other markers of cardiac damage should
be evaluated in clinical practice for a more
in-depth evaluation of cardiac involvement in
acute pancreatitis of different severity. For
example, arginine vasopressin (AVP) also
known as antidiuretic hormone (ADH) is one
of the key hormones for cardiovascular
homeostasis. Despite its pivotal role in car-
diovascular diseases, both the measurement
and the diagnostic use of AVP have never
reached clinical practicability due to the
technical problems related mainly to three
reasons: its short plasma half-life, its interac-
tion with platelets in the serum, and its small
circulating quantity. Another interesting mol-
ecule to test in clinical practice is copeptin, a
glycosylated 39-amino acid long peptide with
a leucine-rich core segment.25 Copeptin and
AVP share the same precursor peptide, the
164-amino acid long preprovasopressin and
copeptin is the C-terminal part of pro-AVP
(CT-pro-AVP) and it is released together with
AVP during precursor processing. In contrast
to AVP, copeptin is very stable in serum or
plasma at room temperature, and is easy to
measure. In contrast to many other biomark-
ers, the copeptin plasma concentration was
similar in different age groups and showed
no correlation with age. A particularly inter-
esting observation was the response of circu-
lating copeptin levels as a result of an acute
myocardial infarction26 since these protein
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Figure 2. Mean and standard deviation of troponin T in 37 patients with acute pancreati-
tis (22 with mild acute pancreatitis and 15 with severe acute pancreatitis). *Indicates P
values of serum concentrations of troponin T at days 2 and 3 compared to day 1. The
other P values refer to the comparison of serum concentrations of troponin T between
mild and severe acute pancreatitis during the three days of the study. 
Figure 1. Pathophysiology of acute pancreatitis.
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levels were higher in patients who died or
were readmitted with heart failure as com-
pared to event-free survivors. Thus, the
measurement of plasma copeptin should be
investigated in acute pancreatitis patients in
order to select those who require more inten-
sive support.
Finally, adrenomedullin (ADM), a 52-
amino-acid peptide elevated in plasma of
patients having heart failure and/or post-
acute coronary syndrome, has been isolated
in human pheochromocytoma and it is also
present in the heart, brain, lung, kidney and
gastrointestinal organs; it has a potent
vasodilator activity due to an increase in
cyclic adenosine monophosphate levels.27 It
should be underlined that the quantification
of ADM is quite difficult due to a short half-
life and the lack of the reliable laboratory
techniques. The identification of mid-region-
al pro-adrenomedullin (MR-proADM)28,29 has
overcome these problems, because it is a sta-
ble peptide possibly reflecting the concentra-
tion of ADM. MR-proADM is probably secret-
ed in equimolar amounts to those of ADM,
and it does not have any physiological effects
which might explain its apparent stability.
Plasma MR-proADM concentrations predict
an adverse outcome in patients in the recov-
ery phase of myocardial infarction and
appear to add information beyond the strong
predictor N-Terminal pro-B-Type natriuretic
peptide (NT-proBNP). There are no studies
on the ADM circulating concentration in
acute pancreatitis patients and this topic
should be explored in order to obtain more
accurate information regarding cardiac
involvement in acute pancreatitis. In any
way, it has been recently reported that MR-
proADM is a strong predictor of rehospital-
ization and mortality in patients with septic
shock28,30 and we believe that this molecule
may have a practical role in patients with
infected pancreatic necrosis. Regarding NT-
proBNP, we have found that this molecule is
abnormally elevated in acute pancreatitis and
its elevation persists for at least 72 hours
(Figure 3). In addition, similar high levels of
serum NT-proBNP are present in patients
with mild acute pancreatitis as well as in
those with severe disease.22 Thus, we should
be aware that elevated values of NT-proBNP
in patients with acute pancreatitis cannot be
useful to detect hearth failure. 
Conclusions
The exact mechanism of myocardial injury
during the course of acute pancreatitis still
remains unclear. In clinical practice, laborato-
ry examinations are needed to distinguish in
the emergency room patients with epigastric
pain having acute pancreatitis from those with
acute myocardial infarction because the treat-
ment strategy of the two diseases differs
markedly. In addition, further efforts should be
made to identify acute pancreatitis patients at
high risk of cardiovascular disease and the
new above-mentioned markers need to be
explored for their possible use in clinical prac-
tice.
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